CORZCore Scientific, Inc.
Is the business good?
The checks split: margins widening, but 3 of 9 health tests passed.
Weak, deteriorating fundamentals. Nine pass/fail tests of year-over-year health from the filings.
Operating margin has widened over the past few years, the business is getting more profitable per dollar of sales.
Where this answer is blind. The F-score rewards improvement, so an already-elite company can score mid-pack.
How good a business is CORZ?
Core Scientific, Inc. spent more than it took in: an operating loss of $561M on $440M of revenue, 12 months to Q2 2026.
Operating loss · on $440M of revenue · 12 months to Q2 2026
- Share count, year on year
- +2.3%
Share count, year on year · shareholders own a smaller slice than a year ago
- Gross margin
- 28%
Gross margin
| Year | Operating margin |
|---|---|
| FY2020 | −10% |
| FY2021 | 24% |
| FY2022 | −329% |
| FY2023 | 1.8% |
| FY2024 | −28% |
| FY2025 | −77% |
Details›
- Gross margin12 months to Q2 2026
- 28%
- Operating margin12 months to Q2 2026
- −127%
- Net margin12 months to Q2 2026
- −325%
- Free cash flow margin
- −218%
- Revenue, trailing twelve months
- $440M
- Free cash flow, trailing twelve months
- −$958M
- Net income, trailing twelve months
- −$1.43B
Margins, capital and share counts from the statements as filed with the SEC; cash conversion is operating cash flow over operating profit after tax.
Software, Infrastructure
Ranks #63 of 78 by RyuScore